ValenzaBio: ProBioGen & ValenzaBio Enter Second Service Agreement
The new program includes upstream and downstream process development and large-scale GMP production.
Read full article »
Chairman & CEO
Patrick J. Crutcher
ValenzaBio is a Maryland-based biopharmaceutical company that develops monoclonal antibody therapeutics for the treatment of autoimmune and inflammatory diseases.
Read more